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Abstract
Clostridium difﬁcile is the leading cause of infectious nosocomial diarrhoea in developed countries, with a measured incidence of
approximately ﬁve episodes per 10 000 days of hospital stay in Europe. Accurate diagnosis of C. difﬁcile infection (CDI) is a prerequisite for
obtaining reliable epidemiological data, but in many European countries diagnosis is probably suboptimal. A signiﬁcant percentage of CDI
cases are missed because clinicians often fail to request tests for C. difﬁcile toxins in cases of unexplained diarrhoea. In addition, some
laboratories continue to use tests of low sensitivity or apply them inappropriately. In one study in Spain, failure to request CDI testing in
more than two-thirds of patients with unexplained diarrhoea led to signiﬁcant underdiagnosis of cases. A recent pan-European survey
revealed huge discrepancies in the rate of CDI testing across Europe, which suggests that epidemiological reports underestimate the true
incidence of CDI in many parts of Europe. This is important because, as this review of the clinical and economic burden of CDI illustrates,
infection with C. difﬁcile imposes a signiﬁcant burden not only on patients, owing to increased morbidity and mortality, but also on
healthcare systems and society in general. On the basis of current incidence rates, annual costs for management of CDI amount to
approximately $800 million in the USA and €3000 million in Europe. Moreover, estimates suggest that costs associated with recurrent CDI
can exceed those of primary CDI. Measures to more effectively prevent CDI and reduce CDI recurrence rates may help to reduce this
burden.
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Introduction
Clostridium difﬁcile is a Gram-positive, spore-forming, anaerobic
bacillus and an important enteropathogen [1]. Responsible for
both hospital-acquired and community-acquired diarrhoea,
C. difﬁcile is now recognized as the leading cause of infectious
nosocomial diarrhoea among adults in industrialized countries
[2], as well as being responsible for outbreaks of infectious
diarrhoea in hospitals all over the world [3]. Colonization of
the gastrointestinal tract occurs via the faecal–oral route
following environmental exposure to C. difﬁcile spores or from
contact with an infected person or healthcare worker, who
acts as a vector. Infection is facilitated by treatment with
antibiotics, and especially broad-spectrum agents, which
disturb the normal colonic microbiota, allowing toxigenic
strains of C. difﬁcile to ﬂourish in the colon [4]. If patients are
unable to mount a protective antibody response, infection can
lead to overt clinical symptoms, which range from mild
diarrhoea to pseudomembranous colitis and toxic megacolon
at the severe end of the disease spectrum [5].
Once regarded as a cause of mildly troublesome antibiotic-
associated diarrhoea in elderly hospitalized patients, C. difﬁcile
is increasingly being seen as a major public health problem in
patients of all ages, hospitalized or living in the community, and
with or without prior antibiotic treatment. In some hospitals,
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the incidence of C. difﬁcile infection (CDI) now exceeds that of
methicillin-resistant Staphylococcus aureus [6].
Increased awareness of CDI, which has extended beyond
the conﬁnes of the medical literature to include the main-
stream media in some European countries, has arisen for
several reasons. These include a marked increase in infection
rates in younger populations [4], increasing severity of disease
accompanied by increases in morbidity and mortality [7,8], and
infection in patients who would not previously have been
considered to be at risk [5]. In light of the recent epidemi-
ological changes in CDI, this review will look at the clinical and
economic impact of CDI on healthcare systems, focusing in
particular on the burden caused by recurrent disease.
The Changing Epidemiology of CDI in
Europe
Evidence for a change in the epidemiology of CDI ﬁrst
emerged in the USA and Canada, where rates of CDI were
seen to increase markedly between 2000 and 2006 [9,10].
Data on discharge diagnosis rates in US hospitals showed that
rates of CDI more than doubled, from <150 000 cases in 2001
to >300 000 in 2005 (http://www.hcup-us.ahrq.gov/reports/
statbriefs/sb50.pdf). This change in incidence marked the start
of what has become a continuous rise in rates of CDI, not only
in North America but also in Europe [11,12].
Historically, rates of CDI in Europe have been broadly
similar to those reported in the USA, although surveillance for
CDI has been more variable, reﬂecting differences in reporting
regulations across Europe. For example, Spain does not
require hospitals to report cases of CDI to the government,
whereas the UK has very strict regulations requiring all cases
to be reported [12]. To address deﬁciencies in CDI reporting
across Europe, a pan-European hospital-based survey of CDI
was carried out in November 2008 to obtain a more complete
overview of CDI in Europe and to build capacity for improved
diagnosis and ongoing surveillance [13]. The survey, which
covered up to six hospitals in each of the 34 countries
surveyed and included data on 395 C. difﬁcile isolates, showed
that CDI remains a predominantly nosocomial infection in
Europe, with 80% of cases being acquired in hospitalized
patients as compared with 14% in the community, and 6%
being of indeterminate origin [13]. The incidence of CDI varied
widely across Europe (as did rates of testing for CDI), with a
mean incidence of nosocomial cases of 4.1 cases per
10 000 patient-days (range: 0.0–36.3). The measured inci-
dence of CDI was relatively low in Spain, France, and Italy, but
very much higher in Scandinavia, Ireland, and the UK [13]
(Fig. 1). In the past decade, the hypervirulent 027 strain of
C. difﬁcile (or North American pulsed-ﬁeld gel electrophoresis
type I or restriction endonuclease analysis group BI, as it is
more usually referred to in North America) has been identiﬁed
as a key driver of the rapid increase in new cases of CDI in
North America [8,14]. However, the pan-European survey
revealed that the overall prevalence of ribotype 027 in Europe
is at present relatively low, at c. 5% [13]. This suggests that
strains other than ribotype 027 may have a more prominent
role in driving increased rates of CDI in Europe. Among the
European countries surveyed, ribotype 078, which is known to
produce disease of similar severity to that caused by
ribotype 027, occurred with a frequency of 8%. Other strains
known to be associated with more severe CDI include
ribotype 018, which occurred with an approximate overall
frequency of 6% and accounted for 80% of all C. difﬁcile strains
in Italy, ribotype 015 (frequency of 3%), and ribotype 056
(frequency of 2%) [13]. The pan-European survey conﬁrmed
the signiﬁcance of older age (65 years), severe comorbidity
and prior antibiotic therapy as risk factors for CDI, with age
65 years, severe pulmonary comorbidity, previous ﬂuor-
oquinolone use and infection with ribotypes 018 and 056 also
being associated with worse outcomes [13].
Accurate diagnosis of CDI is a prerequisite for obtaining
reliable epidemiological data on incidence and prevalence
FIG. 1. The measured incidence of Clostridium difﬁcile infection (CDI) across Europe in 2008 (adapted from Bauer et al. [13]).
ª2012 The Author
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18 (Suppl. 6), 5–12
6 Clinical Microbiology and Infection, Volume 18, Supplement 6, December 2012 CMI
rates, and yet, as a comprehensive survey of diagnostic
protocols across Europe suggests, testing for CDI is subop-
timal in many countries [15]. Recovering C. difﬁcile from
culture enhances the potential for diagnosis by permitting
performance of a ‘second-look’ test for CDI [5]. A signiﬁcant
percentage of CDI cases are missed today because clinicians
often fail to request tests for C. difﬁcile toxins in cases of
unexplained diarrhoea, and some laboratories use diagnostic
tests with low sensitivity or that are not applied appropriately.
A recently completed diagnostic study, in which conﬁrmatory
cultures were performed in our laboratory in Spain on
diarrhoeal samples obtained on a single day from 118 Spanish
laboratories covering 75.4% of the Spanish population, sug-
gests that this is indeed the case [16]. Culture was performed
on 807 diarrhoeal samples from 730 patients aged 2 years.
The results showed that 63 (7.8%) were culture-positive for
C. difﬁcile, with 45 (5.6%) containing toxigenic strains [16].
However, the study revealed that more than two-thirds of
cases went undiagnosed at the original hospital, mainly because
there had been no request for CDI testing by the clinicians,
and 19% had been misdiagnosed at the original hospital
because the tests used in the laboratories were insufﬁciently
sensitive. Had these specimens not been subjected to repeat
testing for CDI at a central laboratory, rates of CDI would
have been signiﬁcantly lower than the incidence of 3.8 cases of
CDI per 10 000 patient-days based on the culture results [16].
Although failure to request testing undoubtedly accounts
for most under-reporting of CDI in Europe, the choice of
diagnostic method may also play a part. For many years, stand-
alone enzyme immunoassays for toxin detection have been
used for CDI detection by most laboratories in Europe [15],
and this probably reﬂects current practice. However, as two
recent reviews have highlighted, these tests lack sensitivity
when used as the sole diagnostic test for CDI [17,18].
Moreover, lack of conﬁdence in such tests has led clinicians to
submit multiple samples from the same patient for repeat
testing, but, as the European Society of Clinical Microbiology
and Infectious Diseases (ESCMID) diagnostic guidelines stress,
such an approach does not increase the rate of CDI detection
in an endemic setting [1]. CDI detection rates can be improved
signiﬁcantly with the use of nucleic acid ampliﬁcation tests for
the detection of genes that encode C. difﬁcile toxins [17,18],
especially when restricted to patients with diarrhoea [17]. The
wider adoption of such tests, several of which are now
commercially available, should, in the longer term, help to
address current deﬁciencies in the laboratory diagnosis of CDI
and lead to better epidemiological reporting in the future.
Cases of CDI may also be missed because they occur
following a patient’s discharge from hospital even though the
patient acquired C. difﬁcile while in hospital. Data from a
retrospective cohort study carried out in the USA show how
inclusion of post-discharge CDI events can substantially alter
hospital-speciﬁc CDI incidence rates (Fig. 2) [19]. Between
2000 and 2007, the hospital-onset CDI incidence increased
from 15 per 10 000 admissions to 22 per 10 000 admissions,
reﬂecting the rising incidence of CDI among hospitalized
patients. When post-discharge CDI events were included in
these ﬁgures, the incidence doubled from 29 per 10 000 in 2000
to 52 per 10 000 in 2007 [19]. Failure to include post-discharge
CDI cases can lead to further under-reporting of CDI and
inaccurate incidence rates. It is widely assumed that, within
hospitals, infected patients are the primary source of onward
transmission of C. difﬁcile to other susceptible patients. How-
ever, a recent study in which molecular typing was used to
match cases of nosocomially acquired CDI in >14 000 patients
with diarrhoea, 1282 of whomhadCDI, showed that, overall, no
more than one-quarter of cases could be linked to an inpatient
source [20]. This suggests that we need to be alert to sources of
C. difﬁcile contamination other than ward-based patient contact
to understand the transmission of nosocomially acquired CDI.
CDI is still predominantly a healthcare-associated (nosoco-
mial) infection; however, when appropriately searched for, it is
also a cause of community-acquired diarrhoea [21–25].
Determining the precise origin of CDI can be difﬁcult, but
classiﬁcation systems have been developed that distinguish
between community-associated CDI and infections that orig-
inate in healthcare facilities where skilled nursing care is
provided, such as hospitals and nursing homes [26]. A
commonly used deﬁnition of community-associated CDI is
that of symptom onset in the community or within 48 h of
FIG. 2. The impact of post-discharge cases of Clostridium difﬁcile
infection (CDI) on the measured incidence over the period 2000–2007
(adapted from Murphy et al. [19]). Reprinted from Infect Control Hosp
Epidemiol, Murphy CR, Avery TR, Dubberke ER et al, with permission
from University of Chicago Press ª 2011 by The Society for
Healthcare Epidemiology of America. All rights reserved. 0899-823X/
2012/3301-0005$15.00. DOI: 10.1086/663209.
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admission to a healthcare facility, provided that symptom
onset occurred >12 weeks after the last discharge from a
healthcare facility [26]. By contrast, healthcare-associated CDI
is deﬁned as symptom onset occurring >48 h after admission
to a healthcare facility [26].
Measured CDI incidence varies markedly across Europe,
and may be inﬂuenced by high rates of testing in some
countries. For example, the pan-European survey revealed
marked differences in the clinical suspicion of CDI, as shown
by the fact that the frequency of testing for infection varied by
more than 47 times between countries (as expressed by the
number of patients tested per 10 000 patient-days) [13].
Greater clinical suspicion of CDI in any patient presenting with
unexplained diarrhoea together with greater awareness of
post-discharge CDI and improved diagnosis will help us to
build a more reliable picture of the true number of cases of
CDI that occur annually in each European country.
The Clinical Burden of CDI
CDI imposes a considerable burden on patients from
increased morbidity and mortality, as well as imposing a
signiﬁcant burden on the healthcare systems of developed
countries. Patients experience considerable morbidity from
the debilitating and profuse diarrhoea that is the hallmark of
CDI. Other debilitating symptoms of mild to moderate disease
can include fever and abdominal distension [5,27]. Where
severe CDI progresses, then inﬂammatory lesions, the forma-
tion of pseudomembranes in the colon, or the development of
paralytic ileus, toxic megacolon and fulminant colitis may occur
[5,27]. Other complications of fulminant colitis include perfo-
ration of the bowel, sepsis, and shock [27].
Within the population of patients at increased risk of
developing CDI, the clinical burden falls disproportionately not
just on the elderly, who are most at risk of acquiring C. difﬁcile
[5], but also on those who have inﬂammatory bowel disease
(IBD) concurrent with CDI [28], those who are seropositive
for human immunodeﬁciency virus (HIV) infection [29], and
those who undergo organ transplantation, particularly those
with hypogammaglobulinaemia [30].
Patients with IBD are particularly susceptible to infection
with C. difﬁcile, the presence of which may be masked by the
fact that diarrhoea is a common symptom of both Crohn’s
disease and ulcerative colitis. The outcome in patients with
IBD can be severely compromised by CDI. A retrospective
cohort study of almost 250 000 patients admitted to hospitals
in England for IBD over a 6-year period showed that, among
the 2402 patients who had IBD and concurrent CDI, death
rates at 1 year were higher (33.1 vs. 6.7%, respectively) and
inpatient stays longer (26 vs. 5 days, respectively) than for
patients with IBD alone, and IBD patients with CDI were also
twice as likely to undergo bowel surgery, including emergency
colectomy [28]. Other groups of patients with compromised
immune systems include HIV-seropositive patients and trans-
plant recipients [29,30]. A recent systematic review of CDI in
HIV-seropositive patients and transplant recipients suggests
that acquisition of CDI is associated with a poorer prognosis in
these patients than in immunocompetent individuals [29]. CDI,
which caused diarrhoea in 43% of hospitalized HIV patients,
and has been identiﬁed as the most common bacterial cause of
HIV-related diarrhoea in other studies [31] and in up to 31% of
transplant recipients, is itself debilitating. It exacerbates the
state of immunosuppression by compromising nutrition and
other factors that inﬂuence immune function. By prolonging
hospitalization and the need for intravenous rehydration, CDI
also increases the risk of hospital-acquired infection, including
re-infection with C. difﬁcile. This, in turn, will drive morbidity
and mortality, particularly in the more severe cases, as
highlighted in a recent review by Collini et al. [29].
Infection with toxigenic strains of C. difﬁcile is a potentially
life-threatening condition, especially among the small but
increasing number of patients who develop fulminant colitis
[32,33]; nonetheless, CDI can still cause death in patients with
less severe disease [34]. Data from the pan-European survey
showed that the overall mortality rate was 22%, with CDI
being directly responsible for c. 2% of all deaths and a
contributor to death in a further 7% of cases [13]. These
rates are much lower than those reported for the UK, where
CDI-attributable mortality rates have exceeded 20% for
several years (http://www.ons.gov.uk/ons/rel/subnational-health2/
deaths-involving-clostridium-difﬁcile/2009/deaths-involving-
mrsa–england-and-wales–2009.pdf). Although CDI-attributable
mortality rates have historically been <2% in North America,
rates have increased in the past decade. Recent data from
three Canadian hospitals, in which death within 30 days of
infection was used as a measure for CDI-attributable mortality,
revealed a mortality rate of 37% [35]. It is suggested that this
measure provides a more accurate estimate than cause of
death on a death certiﬁcate. Conceivably, studies using data
from death certiﬁcates may underestimate the mortality
attributable to CDI, and some rates may actually be higher
than those given in the literature.
The Burden of CDI Recurrence
Most patients with an initial episode of CDI will respond to
treatment with either oral metronidazole or vancomycin.
However, many patients will experience a recurrence of
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diarrhoea within days to weeks of stopping treatment for the
ﬁrst attack [7,36,37]. Recurrence can arise either from a
relapse of the original infection or following re-infection with a
new strain of C. difﬁcile from an exogenous source. Current
treatment guidelines, including those from the ESCMID, argue
that it is impossible in daily clinical practice to distinguish
between relapse and re-infection, and ‘recurrence’ is therefore
used as a generic term for both [27,38]. However, in the
guidelines of the Society for Healthcare Epidemiology of
America and the Infectious Diseases Society of America, it is
suggested that infection occurring after symptom resolution
within 8 weeks of a previous infection is more likely to be a
relapse and to result from treatment failure, whereas infection
occurring >8 weeks after a previous infection (no positive
result within the previous 8 weeks) is more likely to result
from re-infection [38].
Older age, a compromised immune system, diabetes
mellitus, recent surgery (within a month), exposure to more
than three antibiotics, long hospital stays and continued use of
previous antibiotics are among the risk factors for recurrent
CDI [9,39–42]. Other factors associated with recurrent CDI
include prolonged disturbance of the normal colonic micro-
ﬂora, persistence of spores in the gut, and a failure to mount
an effective immune response to C. difﬁcile and its toxins
[41,43,44]. In the pan-European survey described earlier, 18%
of patients experienced recurrent CDI [13], and other studies
have reported rates of up to 25% within 30 days following
treatment with either metronidazole or vancomycin [7,36,45]
(Fig. 3). Even higher rates of 47% following treatment with
metronidazole have been documented in one Canadian study
[9]. Patients who have experienced one recurrent episode of
CDI are at signiﬁcantly increased risk of further recurrences
[37,46]. In one report, 45% of patients (n = 163) experienced
a second recurrence of CDI [46], and in a study in which
patients had had an average of 3.2 prior episodes of CDI, the
recurrence rate was 65% [37] (Fig. 3).
The ESCMID has identiﬁed recurrent CDI as the major
shortcoming of current treatments [27], and it is arguably the
most common complication of treatment with metronidazole
or vancomycin [5,37,47,48]. Patients who experience recur-
rent CDI have to endure prolonged symptoms associated with
the disease [47]. Recurrent CDI leads to repeated courses of
antibiotic treatment and the risk of adverse events as well as
re-hospitalization. Like patients with an acute episode of CDI,
patients with recurrent CDI serve as a reservoir of infection
that can lead to secondary infection in other vulnerable
patients [43].
The Economic Burden of CDI
Given that CDI usually develops in patients who are already
hospitalized for treatment of an underlying condition, the extra
costs associated with the management of CDI could be
expected to be trivial. However, as health economic studies
have demonstrated, the costs associated with each hospital-
ized case of CDI are by no means trivial [49,50]. Patients
colonized with C. difﬁcile who develop CDI require isolation,
supportive therapy for underlying diseases, and speciﬁc
antibiotic therapy to eliminate C. difﬁcile from the bowel. As
compared with the costs of such measures, antibiotic therapy
for CDI represents only a small part of the cost burden, i.e.
c. 1% of the total costs of care [51]. Understandably, drug
acquisition costs in general will vary, depending on local
protocols and the country in which one operates. The
availability of branded vancomycin capsules for oral adminis-
tration and new antibiotics such as ﬁdaxomicin will be relevant
to clinicians managing patients with CDI. However, acquisition
costs for treatments should be considered in the context of
the wider costs of managing CDI. In the small percentage of
patients who develop serious complications, signiﬁcant addi-
tional costs will also arise from the need for surgery and
postoperative care.
On average, patients with CDI spend an extra 1–3 weeks in
hospital as compared with non-infected patients. Increased
duration of hospitalization is a major, if not the major,
FIG. 3. The frequency of Clostridium difﬁcile infection (CDI) recurrence [7,36,37,45,46].
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contributor to increased costs [49]. Additional costs accrue
from the need for rigorous hygiene in patient care, environ-
mental decontamination, and, when outbreaks occur, cohort
isolation and ward closure [11]. Data from a matched case–
control study illustrate the excess costs associated with the
management of CDI. The average total cost of care for each
CDI patient was €33 840, which was greater than the €18 981
cost of care for the control cohort. When the additional cost
of treating CDI was analysed on a per patient episode basis,
this ranged from an extra €4067 to an extra €9276 [50].
Consistent with other studies, CDI patients in this study spent
signiﬁcantly longer in hospital than matched non-infected
controls (a median of 7 days longer; p 0.006). However, the
costs per patient-day were not signiﬁcantly different between
those with CDI and the non-infected controls (€1110 vs.
€1034, respectively) [50]. These ﬁndings are supported by data
from a systematic review of the healthcare costs associated
with caring for patients with primary and recurrent CDI [52].
Based on the results from 13 studies that met inclusion
criteria, the analysis showed that total costs in 2008 US dollars
for treating primary CDI ranged from $9822 to $13 854, as
compared with $6950 to $9008 for controls. Costs escalated
in patients with signiﬁcant comorbidity, such as IBD patients,
where costs were $22 873 per case as compared with
$15 762 for non-infected IBD patients [52]. As expected, the
attributable or incremental costs associated with CDI
(Table 1) were largely attributable to increased duration of
hospitalization [52]. With the use of data derived from this
systematic review and estimated annual cases of CDI in the
USA, attributable healthcare costs of CDI in the USA were
estimated to be in the range of $433 million to $797 million
per year [52]. These estimates are consistent with ﬁgures of
$496 million to $797 million per year obtained from an
economic model that was designed to simulate the costs
associated with CDI from the perspective of the hospital,
third-party payer, and society in general (Table 2) [53].
Separately, the high rates of recurrent CDI associated with
currently available antibiotics not only increase morbidity, with
some patients experiencing repeated recurrences over months
and years, leading to exhaustion and protein-losing enterop-
athy [27], but also add to the burden of costs of care.
Additional costs arise from extended re-hospitalization, labo-
ratory tests to conﬁrm a recurrent infection, and the cost of
additional and often extended antibiotic treatment. Data from
the systematic review showed that total costs for recurrent
CDI were approximately three-fold higher than for a primary
episode of CDI [52].
As these data demonstrate, the economic consequences of
CDI are substantial, and often exceed the costs of treating
other hospital-acquired infections, such as viral gastroenteritis
[53]. In Europe alone, estimates suggest that the potential
costs associated with the management of CDI are in the region
of €3000 million [11]. This ﬁgure is likely to rise in line with an
ageing population: by 2050, >134 million Europeans will be
aged 65 years [11]—the segment of the population most at
risk of contracting CDI.
As this review has illustrated, CDI imposes a considerable
burden on patients from increased morbidity and mortality, as
well as imposing a signiﬁcant burden on the healthcare systems
of developed countries. From a European perspective, the
ﬁndings presented here are consistent with those from a
systematic review recently published by Wiegand et al. [54].
Using country-speciﬁc estimates and weighting by sample size,
the authors showed that the 30-day mortality from CDI
ranged from 2.8% to 29.8% across Europe, with CDI patients
spending anywhere between 16 and 37 extra days in hospital.
More effective measures to prevent primary cases of CDI and
TABLE 1. Attributable or incremental costs associated with
the management of Clostridium difﬁcile infection (CDI) in
hospitalized patients [52]
Study description Location Year
Attributable or
incremental costs
associated with
CDI in 2008 US
dollars
Retrospective chart
review (n = 155)
USA 1991 9099
Prospective case–control
study (n = 142)
UK 1996 9277
Prospective cohort study in recurrent
CDI (n = 209)
USA 1999 2626
Retrospective study (n = 87) Ireland 2000 6890
Prospective study (n = 271) USA 2002 3669
Laboratory-based prevalence
study (n = 2062)
Canada 2002 12 099
Retrospective cohort study
(n = 3692)
USA 2007 13 675
Retrospective study
(n = 8133)
USA 2007 77 483
Retrospective cohort study
(n = 1835)
USA 2007 5325–27 290
Retrospective cohort study
(n = 24 691)
USA 2008 2454–5042
Retrospective study in IBD
patients (n = 44 400)
USA 2008 11 000
IBD, inﬂammatory bowel disease.
Reprinted from Ghantoji et al. [52]. Copyright (2010), with permission from the
Healthcare Infection Society.
TABLE 2. Costs associated with Clostridium difﬁcile infection
(CDI) from the hospital, third-party payer and societal
perspective in the USA [53]
Median cost per case of CDI (in 2010 US dollars)
Hospital perspective 9179–11 456
Third-party payer perspective 8932–11 679
Societal perspective 13 310–16 464
Annual burden of CDI (in 2010 US dollars)
Hospital perspective 496 million
Third-party payer perspective 547 million
Societal perspective 796 million
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reduce the frequency of CDI recurrence would represent an
important advance in reducing the costs associated with this
pernicious nosocomial pathogen.
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